Isoprenoid precursors, which are a large group of natural products and play key roles in many biological pathways, can only be biosynthesized by the 2-C-methyl-D-erythritol 4-phosphate pathway in Mycobacterium tuberculosis. The 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase (IspE), which is an essential enzyme in the isoprenoid precursor biosynthesis pathway, catalyzes ATP-dependent phosphorylation of 4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME) to 4-diphosphocytidyl-2C-methyl-D-erythritol-2-phosphate and plays a crucial role in M. tuberculosis survival. Therefore, IspE is characterized as an attractive and potential target for antimicrobial drug discovery. However, no experimental structure of M. tuberculosis IspE has been reported, which has hindered our understanding of its structural details and mechanism of action. Here, we report the expression and purification of fully active full-length M. tuberculosis IspE and solve the high-resolution crystal structures of IspE alone and in complex with either the substrate CDP-ME or nonhydrolyzable ATP analog or ADP. The structures present a characteristic galactose/ homoserine/mevalonate/phosphomevalonate kinase superfamily ␣/␤-fold with a catalytic center located in a cleft between 2 domains and display clear substrate and ATP binding pockets. Our results also indicate distinct differences in ligand binding of M. tuberculosis IspE with other reported IspEs. Combined with the results of mutagenesis and enzymatic studies, our results provide useful information on the structural basis of IspE for future anti-M. tuberculosis drug discovery targeting this kinase.-Shan, S.
MYCOBACTERIUM TUBERCULOSIS is currently one of the most widespread human pathogens; it is responsible for millions of deaths annually and nearly 10 million new infections every year. Unfortunately, this situation has recently been exacerbated due to poor living conditions, coinfection with human immunodeficiency virus (HIV), and the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains (1, 2) . Currently approved anti-M. tuberculosis drugs may have limited effectiveness in the event of the emergence and reemergence of MDR and XDR M. tuberculosis pandemics; therefore, identifying new drug targets and understanding the underlying mechanisms of these targets are crucial for the development of new anti-M. tuberculosis therapies (3) .
Isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP) are the precursors of isoprenoids, an extensive group of natural products consisting of essential primary and secondary metabolites (e.g., dolichol, ubiquinones, carotenoids, and sterols) that contribute to many important biological functions, including electron transport, photosynthesis, apoptosis, meiosis, protein cleavage and degradation, and hormone-based signaling (4 -6) . In the life cycle of M. tuberculosis and several other bacterial pathogens, isoprenoids play crucial roles in the biosynthesis of structural components of the cell wall, and thus are characterized as attractive and potential targets for antimicrobial drug discovery (7, 8) .
Currently, 2 different routes have been identified to biosynthesize IPP and DMAPP: the well-known mevalonate pathway in mammals, higher plants, archaea, and most eukaryotes (9, 10) ; and the 2-C-methyl-d-erythritol 4 phosphate (MEP) pathway, which is also known as the 1-deoxy-d-xylulose-5-phosphate (DOXP) or nonmevalonate pathway, in bacteria, plant plastids, and especially in several pathogenic microorganisms (e.g., M. tuberculosis and Plasmodium falciparum; ref. 11). The MEP pathway consists of 8 steps and 7 enzymes (12): DOXP synthase; DOXP reductase, 4-diphosphocytidyl-2-C-methyl-derythritol synthase (IspD); 4-diphosphocytidyl-2-C-methyld-erythritol kinase (IspE); 2-C-methyl-d-erythritol 2, 4-cyclodiphosphate synthase (IspF); (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMB-PP) synthase (IspG); and HMB-PP reductase (LytB or IspH) (13) . Because the MEP pathway is vital for M. tuberculosis survival and absent in mammalian cells, it is an attractive potential antimicrobial drug target (14 -18) . Indeed, fosmidomycin (3-[formyl(hydroxy)amino] propoylphosphonic acid), an antibiotic used in clinical trials to treat malaria (19) , targets on inhibiting its second step of the MEP pathway (20) . This result suggests that compounds that can inhibit the MEP pathway may be potential anti-M. tuberculosis drug candidates.
Our research concentrates on the fourth step of the MEP pathway, in which the IspE converts 4-diphosphocytidyl-2-C-methyl-d-erythritol (CDP-ME) to 4-diphosphocytidyl-2-C-methyl-d-erythritol-2-phosphate (CDP-ME2P) in an ATP-dependent manner ( Fig. 1) . IspE has been identified as one of the genes that is crucial for pathogenic bacteria survival and was recently shown to be essential in Mycobacterium smegmatis (21) . Due to its importance in bacteria and absence in mammalian cells, IspE has long been considering an ideal antibacterial drug target (22) and the deeper research on M. tuberculosis IspE will help us find the better way to treat M. tuberculosis.
Previous results indicate that the IspE belongs to the galactose/homoserine/mevalonate/phosphomevalonate (GHMP) kinase superfamily, which is named after several different proteins in mammals (e.g., galactose kinase, homoserine kinase, alonate kinase, and phosphomevalonate kinase; refs. 23, 24) . Currently, 3 crystal structures of M. tuberculosis IspE orthologues have been reported: the Escherichia coli orthologue (E. coli IspE) in complex with the ATP analog adenosine 5Ј-(␤,␥-imino)triphosphate (AMP-PNP) and the substrate CDP-ME in 2003 (13) , the Aquifex aeolicus IspE (25) , and the Thermus thermophilus IspE, and they all tallied with great GHMP superfamily character (13) . The amino acid sequence similarities between these 3 enzymes and the M. tuberculosis IspE suggest similar overall structures and enzymatic mechanisms. However, no experimental structure of M. tuberculosis IspE has been reported, which has hindered our understanding of its structural details and mechanism of action (13, 22) .
Here, we report the construction, expression, and purification of full active full-length recombinant M. tuberculosis IspE. We also determined the 3-D crystal structure of apo M. tuberculosis IspE, as well as in the complex containing either substrate or AMP-PNP or ADP, providing structural details to complement our enzyme study and future drug discovery efforts targeting the M. tuberculosis IspE to treat MDR and XDR strains.
MATERIALS AND METHODS

Protein expression and purification
We used primers 5Ј-TGCAACTCATATGGTCAGT-GAAGCGTCCG-3Ј (F) and 5Ј-CATCTCGAGTTCAGCCACG-TACTACACCA-3Ј (R) to amplify the gene encoding the 306-aa full-length IspE from M. tuberculosis H37Rv. The target gene was inserted into the pET-28a vector (Novagen, San Diego, CA, USA) using the NdeI and XhoI (bold and underscored in the primers) restriction sites.
The recombinant plasmid was transformed into E. coli strain BL21 (DE3) and overexpressed as a 6xHis-tag fusion protein. The cells were grown with shaking for 4 -5 h at 37°C in 1 L Luria-Bertani medium containing 50 g/ml kanamycin until the OD 600 reached 0.4 -0.6. Then, the cells were transferred to 16°C, and IspE expression was induced by incubation for 16 -20 h in the presence of 0.3 mM IPTG. The cells were harvested; resuspended in 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 10 mM imidazole, and 5 mM ␤-mercaptoethanol (␤-ME); and then lysed by sonication. The lysate was centrifuged at 16,000 g for 35 min to remove cell debris.
The supernatant was loaded twice onto a Ni-NTA column (Qiagen, Valencia, CA, USA) equilibrated with lysis buffer. Nonspecifically bound proteins were washed off with 5 column volumes of 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 30 mM imidazole, and 5 mM ␤-ME; the target protein was eluted with 20 mM Tris-HCl (pH 8.0), 500 mM NaCl, 100 mM imidazole, and 5 mM ␤-ME. Eluted protein was dialyzed against 20 mM Tris-HCl (pH 7.0), 50 mM NaCl, 1 mM DTT, and 20 U thrombin overnight at 4°C to remove the N-terminal 6xHis tag and then reloaded onto the Ni-NTA column to remove the cleaved tag. Relevant mutants were generated by site-directed mutagenesis and purified via the same procedure.
The recombinant IspE was further purified using a Resource Q anion exchange column (GE Healthcare, Little Chalfont, UK) and a Superdex-200 gel filtration column (GE Healthcare) according to the manufacturer's recommendations. Fractions were analyzed with SDS-PAGE, and the purity was Ͼ95%. The purified protein was finally concentrated to 15 mg/ml in 20 mM Tris-HCl (pH 7.0), 50 mM NaCl, and 5 mM DTT for crystallization.
Crystallization
Crystallization of the M. tuberculosis IspE was performed at 18°C using the hanging-drop vapor-diffusion method. The crystals grew in drops containing 1 l IspE and 1 l reservoir solution against 200 l reservoir solutions. Small and twin crystals appeared after 1 mo of growth in 0.1 M bis-tris propane (pH 7.0) and 3.2 M NaCl, with poor diffraction quality after initial screening. Microseeding was used to optimize the crystals to a final size of 80 ϫ 80 ϫ 100 M, which diffracted to 2.1 Å. IspE in complex with different small molecules was prepared from crystals grown in 0.1 M bis-tris propane (pH 7.5) and 1.5 M Li 2 SO 4 by soaking them for 16 h at 18°C in a mixture consisting of reservoir solution and small molecules (60 mM CDP-ME and/or saturated AMP-PNP or saturated ADP). The crystals were then soaked in a cryoprotectant solution consisting of the reservoir solution and 20% (v/v) glycol and then flash-frozen in liquid nitrogen for X-ray diffraction data collection.
Data collection, processing, and structure determination
The apo-IspE crystal diffracted to 2.1-Å resolution at 100 K using a Rigaku FR-E rotating anode generator with an R-Axis IVϩϩ image plate (Rigaku, Tokyo, Japan) at 45 kV and 45 mA, while the complex crystal data were collected with a Rigaku MM-007 rotating anode generator with an R-Axis IVϩϩ image plate at 40 kV and 20 mA. Data were processed, integrated, and scaled using the HKL2000 package (26) . The crystals belong to the P2 1 2 1 2 1 space group with unit cell parameters of a ϭ 52.5 Å, b ϭ 72.3 Å, c ϭ 107.3 Å, and ␣ ϭ ␤ ϭ ␥ ϭ 90°. There is only 1 molecule/asymmetric unit, with a Matthews coefficient of 3.4 Å 3 /Da, corresponding to 63% solvent content (27) .
The Phaser program (28) was used to find the correct solution via the molecular replacement method, using the T. thermophilus IspE crystal structure [Protein Data Bank (PDB) code 1UEK; shares 38% sequence identity with the M. tuberculosis IspE] as the initial searching model. Subsequently, the M. tuberculosis apo-IspE crystal structure was used as a starting model to solve the structure of the M. tuberculosis IspE in complex with ligands.
Manual model building and refinement were performed with Coot (29) and Phenix (30) . During the later stages of positional refinement, restraints were relaxed, and a bulk solvent correction was applied under the guidance of R free . Model geometry was verified using the program ProCheck (31) . Solvent molecules were located from stereochemically reasonable peaks in the A-weighted F o -F c difference electron density map. Final refinement statistics are summarized in Table 1 . Structural figures were drawn with the program PyMOL (32).
M. tuberculosis IspE enzymatic assay
M. tuberculosis IspE activity was determined by a spectrophotometric assay that uses pyruvate kinase and l-lactate dehydrogenase as auxiliary enzymes to transfer the action of the IspE activity to an observable decrease in the absorption of NADH at 340 nm (33) . To measure the kinetic properties of wild-type IspE and relevant mutants, enzymatic assays were conducted based on the activity of IspE observed above. Briefly, we used 100 mM Tris-HCl (pH 7.5), 1 mM DTT, 20 mM KCl, 10 mM MgCl 2 , 0.45 mM NADH, 4 mM phosphoenolpyruvate, 8 U pyruvate kinase, 9 U lactate dehydrogenase, 5 g M. tuberculosis IspE, and 1.5 mM ATP, which was added last, in a total volume of 50 l. The reaction mixture was incubated at 37°C for 5 min, and the A 340 value was measured using a Thromo spectrophotometer (Thermo Scientific, Waltham, MA, USA) immediately after adding an additional 1.5 mM ATP.
RESULTS AND DISCUSSION
Overall M. tuberculosis IspE structure
The crystal structure of the 31-kDa, full-length apo-IspE was solved by the molecular replacement method and refined to 2.1-Å resolution, resulting in a final R work value of 19% (R free ϭ24%). The crystal belongs to the P2 1 2 1 2 1 space group, and there is 1 IspE monomer/ asymmetric unit, with a Matthews coefficient of 3.4 Å 3 /Da (corresponding to 63% solvent content; ref. 34 ). The first 4 N-terminal residues are missing due to a lack of density, which did not affect the correct molecular folding of the entire structure. Gel filtration and analytical ultracentrifugation (data not shown) show that IspE exists as a monomer in solution, which is consistent with the crystallographic result and suggests that the monomer is the biological unit in vivo.
The M. tuberculosis IspE displays a compact, cylindrical, 60-ϫ 50-ϫ 35-Å structure consisting of 2 relatively separated domains: the ATP binding domain (N-terminal domain) and substrate binding domain (C-terminal domain), which is the canonical GHMP kinase fold (35) . The ATP binding domain (residues Met1-Gly148) consists of 4 ␤ strands (␤1, ␤4, ␤5, and ␤6), 4 ␣ helices (␣1 to ␣4), and 1 3 10 helix (1), while the substrate binding domain is composed of 10 ␤ strands (␤2, ␤3, and ␤5 to ␤13) and 6 ␣ helices (␣5 to ␣10) ( Fig. 2A) . ␤1, ␤4, ␤5, and ␤6 form a 4-strand ␤ sheet; ␤4 is antiparallel to the other 3. The concave side of this 4-strand ␤ sheet is linked to 4 ␣ helices to form the N-terminal domain. This 4-stranded ␤ sheet and another (consisting of ␤6 and ␤9, ␤11, ␤12, and ␤13) are wrapped in the middle of 6 ␣ helices to form the main structure of the C-terminal domain.
The 3 known conserved motifs in the GHMP kinase superfamily that are involved in creating the catalytic center are also found in the M. tuberculosis IspE (21) . Motif A (Lys13 to Leu18), which is located in the ␤2 strand, is involved in forming the substrate binding site. Motif B (Gly102 to Ser107) is a glycine-rich phosphate binding loop, which is located in the loop between ␤6 
TABLE 1. X-ray data collection and refinement statistics
Parameter CDP-ME kinase CDP-ME kinase/CDP-ME CDP-ME kinase/AMP-PNP CDP-ME kinase/ADP and ␣2 and interacts with the triphosphate moiety of ATP. Moreover, motif B is also described as the P loop, which is found in the septin family and some NTP hydrolases (36) . Motif C (Val254 to Gly258), which is located in the loop between ␤11 and ␤12, helps to stabilize the conformation of motifs A and B rather than interacting with ligands directly. Thus, motif C is likely a linker to sustain the stability of motifs A and B, akin to a corner of a triangle that stabilizes the other 2 corners. All these motifs together create the catalytic center ( Figs. 2A and 3B) (1) between ␤3 and ␣1 in the M. tuberculosis structure. Further, the C terminus of M. tuberculosis IspE (which is longer than in the T. thermophilus IspE) forms a ␤ strand that is missing in the T. thermophilus IspE structure, and the loop between ␣1 and ␤4 is slightly different (Fig. 3A) .
Substrate and ATP binding sites
Because the substrate and ATP binding sites are potential sites for drug design targeting in protein kinases, which has been well demonstrated with cyclin-dependent kinases (CDKs), mitogen-activated kinases (MAPKs), glycogen synthase kinase 3 (GSK-3), and CDK-like kinases (CLKs) (38) , it is crucial for us to know the precise substrate and ATP binding sites in the M. tuberculosis IspE. Therefore, we determined the high-resolution crystal structures of M. tuberculosis IspE in complex with its substrate CDP-ME, the stable ATP analog AMP-PNP, and the reaction product ADP, respectively. Although our efforts to obtain the ternary structure of IspE in complex with its substrate and ATP ultimately failed, our results still present a trusted model of the M. tuberculosis IspE in complex with substrate and ATP at the atomic level and shed light on its enzymatic mechanism. The K m and V max of CDP-ME and ATP were determined to be 666.7 m and 3.0 m/min and 285.7 m and 3.0 m/min, respectively. Our CDP-ME data are consistent recently reported M. tuberculosis IspE kinetic parameters (21), but our ATP values are higher, which may be due to the different in vitro conditions used.
The CDP-ME binding site is a deep cavity between the substrate binding domain and the ATP binding domain, which is formed by ␤3, ␤4, ␣4, and the loop regions linking ␤3 to ␤4 and ␤7 to ␤8 (Fig. 2A) .The cytosine moiety of CDP-ME is deeply buried in the cavity, sandwiched by the aromatic side chains of Tyr28 and Tyr185. These 2 residues stabilize the cytosine moiety with -stacking interactions to fix the position of CDP-ME. Tyr185 is conservatively replaced by phenylalanine in E. coli IspE but not in the A. aeolicus IspE. Tyr28 plays an key role in cytosine head binding due to its nearly 90°conformational change after CDP-ME binding, i.e., from parallel to the ␤2-␤3 loop to vertical relative to the ␤2-␤3 loop (Fig. 4A, B) . These aromatic residues in the active site may act as a doorkeeper to close the site during substrate binding and open it for product release. His29 also participates in stabilizing the cytosine head by forming 3 hydrogen bonds with the pyrimidine. The His29 imidazole ND1 and amide in the main chain donate hydrogen bonds to the cytosine O2 and N3, respectively, of CDP-ME, and the His29 main-chain carboxyl accepts another hydrogen bond from cytosine N4. This interaction is conserved in other IspE substrate binding pockets (Fig. 4A) .
The CDP-ME ribose position is directed out of the cleft formed by Tyr28 and Tyr185 and has access to the solvent. Based on the chemical bonds with the cytosine head, the ribose and phosphates are clearly in the density map, though they lack direct interactions with the other residues. The ␣-phosphate accepts a hydrogen bond from Tyr28 the hydroxyl. The CDP-ME tail inserts into the catalytic center, where the catalytic key residues Lys13 and Asp140 are found. There is a network of hydrogen bonds with and around the catalytic residues and ATP to achieve the catalytic reaction. However, without the ATP cofactor present, the density of the erythritol moiety is not clear, making the CDP-ME tail flexible. This flexibility of CDP-ME may regulate the insertion depth of the erythritol moiety by changing its conformation to control different reaction steps. The loop linking ␤7 and ␤8 is also altered in the structure containing CDP-ME. This loop is flexible in apo-IspE, but in the IspE-CDP-ME structure, a network of watermediated interactions stabilizes the loop.
The ATP binding site is in a cavity in the N-terminal domain that is surrounded by the loop linking ␤6 to ␣2 and the loop linking ␤5 to ␣1. This cavity also includes a 3 10 helix and is positioned adjacent to the CDP-ME binding site. In our structures, the 2 different ligands (ADP and AMP-PNP) display different binding conformations. In the structure containing AMP-PNP, only 3 phosphates can be unambiguously determined. This lack of clear density may be due to the flexibility of adenine in the binding pocket when no CDP-ME is present. The 3 phosphates can be clearly observed near the glycine-rich loop, where 7 hydrogen bonds are involved in binding. The O2G atom of the ␥-phosphate is stabilized by Gly102 via a 3.1-Å hydrogen bond with the carboxyl O atom, and the O3G and O1G atoms of the ␥-phosphate share a hydrogen bond with Wat169 and Wat16, respectively. Similarly, Wat16 also forms a 2.7-Å hydrogen bond to Ser107. The linker NB3 atom and the O2B atom of the ␤-phosphate accept hydrogen bonds donated from the main-chain amides of Met103 and Gly102, respectively. The ␣-phosphate forms 2 hydrogen bonds: between the O3A atom and Wat46 (2.8 Å) and the O2A atom and main-chain amide of Ala100 (2.9 Å). These residues and water form a hydrogen bond network to firmly fix the phosphate portion of AMP-PNP in place (Fig. 4C) .
The ADP binding conformation is different from that in the AMP-PNP-bound structure, which likely reflects the ADP-release step of the catalytic cycle. Such a conformation was not previously observed in the E. coli or A. aeolicus IspE structures. The adenine and ribose are solvent accessible, and a lack of interactions with the IspE residues results in vague density. The phosphates are still bound near the P loop, but their positions are slightly different to those in AMP-PNP. The O1B and O2A atoms of the ␣-phosphate accept hydrogen bonds donated by the main-chain amide of Ala104 and Ala100, respectively, whereas the O2A atom forms a water-mediated interaction with Lys95. The O1B and O3B atoms of the ␤-phosphate contact the main-chain amide of Gly102 and Met103 at distances of 2.7 and 2.9 Å. These residues may participate in the process of releasing the ADP product from the channel (Fig. 4D) .
Although our attempts to generate the ternary complex of both factors failed, the amino acid conservation in active sites between the IspE orthologues in E. coli, T. thermophilus, A. aeolicus, and other members of the GHMP kinase superfamily indicates that Lys13 and Asp140 should also participate in the enzymatic reaction. Mutagenesis and enzymatic assessments of the K13A and D140A mutants demonstrated that both mutations perturb catalysis, confirming our hypothesis of the crucial role of Lys13 and Asp140 (Fig. 4E) .
Moreover, although divalent cations are reported to play an essential role in the catalytic reaction (21), we did not observe any ordered density from metal ions in any of the 4 structures, despite the facts that relevant cations were added to the crystal growth solutions and the enzyme displayed normal catalytic activity. Indeed, metal ions are also absent in the E. coli (39) and A. aeolicus (25) IspE structures.
Implications for drug design targeting IspE
The structures of M. tuberculosis IspE alone and in complex with its substrate and ADP/AMP-PNP shed light on the detailed interactions of these molecules and the precise mechanism of catalysis. Combined with our mutagenesis study, these structural data provide valuable information for the development of new drugs targeting M. tuberculosis IspE that may ultimately be used to treat MDR and XDR infections.
While the observed interaction details between the substrate and IspE focus on the cytosine moiety, the interaction mainly involves the phosphates in the ATP binding site. These results suggest that new inhibitors designed for competitive inhibition should focus on altering the cytosine head to a high affinity state in order to decrease the activity of the kinase or to take the ATP binding site with a higher affinity than ATP. In addition, the new inhibitors can be designed by focusing on the CDP-ME tail, which may inhibit IspE function by restraining tail flexibility. We designed 6 mutants (e.g., Y28A, A100F, G102F, M103F, A104F, and Y185A; Fig. 4E ) for structure/function and enzymatic studies to determine the residues involved in binding. Our enzyme activity assays showed that phosphate transfer by all these mutants was completely inhibited, indicating that the residues responsible for the binding interactions with CDP-ME and the cofactor AMP-PNP are crucial for catalysis.
On the basis of the crystal structures, we may be able to design compounds with high binding affinity to block the favorable interactions between M. tuberculosis IspE and CDP-ME or ATP. For example, the side chain of the G106F mutant blocks the binding pocket from the ribose moiety of ATP, and loss of the benzene ring in the Y28A and Y185A mutant decreases the interaction with the CDP-ME cytosine head, thus increasing the flexibility of the substrate. In addition, the change of side chain of the A100F, G102F, M103F, and A104F mutant blocks the ATP binding site, decreasing the size of the binding pocket. In summation, this mutant work suggests targets in the M. tuberculosis IspE structure for new drug design is an operable plan.
CONCLUSIONS
The IspE is involved in the fourth step in the bacterial MEP pathway, which is crucial for the survival of many pathogens and is absent in mammalian cells. Thus, it has been characterized as an attractive and potential drug target to treat M. tuberculosis infection. Here, we report the high-resolution crystal structures of the M. tuberculosis IspE alone and in complex with substrate CDP-ME, the nonhydrolyzable ATP analog AMP-PNP, or ADP, and we provide an efficient method to produce soluble and stable full-length recombinant protein for research on crystal structure and high-throughput screening of small molecular inhibitors. The structures show clear details of interaction among the substrate, ATP, and residues and make it feasible to compare with other reported IspEs in ligand binding. The mutant enzyme activity results indicate that the key residues participated in CDP-ME and ATP binding are crucial for the enzyme function and destruction of the interaction can decrease the enzyme activity.These M. tuberculosis IspE crystal structures and the mechanistic insight gleaned from them lay the foundation for future structure-based drug design and high-throughput screening of small molecular inhibitors to treat M. tuberculosis infection worldwide. 
